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Abstract
Background: Building on an approach developed to assess the economic returns to cardiovascular research, we
estimated the economic returns from UK public and charitable funded cancer-related research that arise from the
net value of the improved health outcomes.
Methods: To assess these economic returns from cancer-related research in the UK we estimated: 1) public and
charitable expenditure on cancer-related research in the UK from 1970 to 2009; 2) net monetary benefit (NMB), that
is, the health benefit measured in quality adjusted life years (QALYs) valued in monetary terms (using a base-case
value of a QALY of GB£25,000) minus the cost of delivering that benefit, for a prioritised list of interventions from
1991 to 2010; 3) the proportion of NMB attributable to UK research; 4) the elapsed time between research funding
and health gain; and 5) the internal rate of return (IRR) from cancer-related research investments on health benefits.
We analysed the uncertainties in the IRR estimate using sensitivity analyses to illustrate the effect of some key
parameters.
Results: In 2011/12 prices, total expenditure on cancer-related research from 1970 to 2009 was £15 billion. The
NMB of the 5.9 million QALYs gained from the prioritised interventions from 1991 to 2010 was £124 billion.
Calculation of the IRR incorporated an estimated elapsed time of 15 years. We related 17% of the annual NMB
estimated to be attributable to UK research (for each of the 20 years 1991 to 2010) to 20 years of research
investment 15 years earlier (that is, for 1976 to 1995). This produced a best-estimate IRR of 10%, compared with 9%
previously estimated for cardiovascular disease research. The sensitivity analysis demonstrated the importance of
smoking reduction as a major source of improved cancer-related health outcomes.
Conclusions: We have demonstrated a substantive IRR from net health gain to public and charitable funding of
cancer-related research in the UK, and further validated the approach that we originally used in assessing the
returns from cardiovascular research. In doing so, we have highlighted a number of weaknesses and key
assumptions that need strengthening in further investigations. Nevertheless, these cautious estimates
demonstrate that the returns from past cancer research have been substantial, and justify the investments© Glover et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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Estimating the returns from biomedical and health research
Estimating the economic returns arising from health
research develops our understanding of how research
translates from ‘bench to bedside’, can be used in advocat-
ing the case for future investments in medical research,
and demonstrates accountability for public and charitable
research funding to taxpayers and donors. Because re-
sources used for publicly and charitably funded medical
research, including cancer research, could potentially be
put to other purposes for the benefit of society, there is an
obligation to demonstrate that such investments represent
good value. In the medical field, it is possible to identify
illustrative examples of specific research breakthroughs
that have contributed to substantial benefit in terms of
life-saving interventions, or to major improvements in the
quality of life of patients with a chronic disease. However,
it is much more difficult to describe systematically the na-
ture and extent of the returns to the investment of a whole
body of medical research, some of which may inevitably
be less fruitful. Furthermore, there are tensions between
advocacy, where interested parties are arguing for more
research funding, and more dispassionate analysis, which
might conclude that too much money is being spent on
research. As noted in an editorial in Nature in 2010: ‘Most
of the attempts to count the economic benefits of invest-
ment in science have been derived from the efforts of
lobbying groups and funding agencies to justify science
spending’ [1].
The literature that assesses the value of the benefits of
medical research forms a relatively small field in terms
of methodology and quality [2,3]. There is a lack of clear
consensus about key issues, such as the best methods to
use to assess the value of the health gains, and there is
also variability in the extent to which studies have in-
cluded all the important components required for a full
analysis of the cost-effectiveness of investing in research.
As summarised in Table 1, Mushkin [4], in an early study,
used a human capital approach to value health gains from
all US biomedical research in terms of the productivity
gains from having a healthy workforce [4]. This approach
has various weaknesses, which were recognised by Mushkin
and others [5], including that it tends to overstate the
benefits when lost labour can be replaced by unemployed
people or through migration, and it undervalues health
gains for groups such as the elderly. Funding First [6] ad-
vanced the field by building on a different approach based
on estimates of the average willingness of individuals to
pay for small reductions in the risk of death. They used
this figure to value the increased longevity of the US
population. In a background paper for this, Murphy and
Topel [7] calculated the enormous economic value that
would come from finding a cure for cancer and other
diseases, but to date, and using the methods they hadadopted, the Funding First report claimed ‘the largest
returns to investment in medical research have come
principally from gains against heart disease and stroke’
([6], page 3).
A broadly similar approach was adopted in a series of
Australian studies conducted by Access Economics (2003,
2008 and 2011) [8-10], but expanded to allow for im-
provements in quality of life based on disability adjusted
life years (DALYs). In the 2003 version of the report, no al-
lowance was made for the elapsed time between research
(input) and improved health and wellbeing (outcome). In
the 2008 and 2011 iterations, this was addressed by pro-
jecting potential health and wellbeing gains 40 years into
the future. In the 2011 report, the authors focused on esti-
mating a return on investment for five specific diseases,
including cancer.
To date, only three studies that we are aware of have
examined the economic returns from cancer research.
Two of those focused on the costs and benefits of US
President Nixon’s ‘War on Cancer’ [11-13]. Litchenberg
[11] in 2004 examined the contribution of pharmaceutical
innovation to increases in cancer survival rates, by looking
at the number of new drugs that had been approved to
treat cancer after 1971 (when the War on Cancer was
declared), and modelling the impact on cancer mortality
rates in the US. He estimated that the increase in approved
drugs accounted for about 50 to 60% of the increase in
age-adjusted cancer survival rates. Although Litchenberg
[11] did not compute a rate of return, he did note that the
drug costs to achieve an additional year of life per person
diagnosed with cancer were well below estimates for the
value of a statistical life. Pertinent to the approach adopted
in the current study, he concluded: ‘Ideally, we would have
measured the effects of new cancer drugs on the number
of quality adjusted life years (QALYS), but were unable to
do so due to lack of data’. In two related papers, Sun et al.
[12] and Lakdawalla et al. [13] followed a similar concep-
tual approach in quantifying the value of gains in cancer
survival, but directly compared this with the costs of
research and development (R&D). They estimated that
improvements in cancer survival in the US between 1988
and 2000 created 23 million additional life years, equiva-
lent to roughly US$1.9 trillion of additional social value,
implying that the average life year gained was worth US
$82,000. As with Litchenberg [11], Sun et al. did not
calculate a return on investment but noted that ‘These
calculations suggest that from the patient’s point of view,
the rate of return to R&D investments against cancer has
been substantial.’ The third study to look explicitly at
cancer is the Deloitte Access Economics study [10] cited
above. In that report, the authors looked at the rate of
return from current (2000 to 2010) research investment in
cancer by the Australian National Health and Medical
Research Council (NHMRC) and compared this with
Table 1 Methods used in various studies to assess the benefits from health research
Study/features Mushkin
(1979) [4]
Funding first
(2000) [6]
Access economics
(2003) [8]
Access economics
(2008) [9]
HERG et al.
(2008) [3]
Access economics
(2011) [10]
How health gains
were assessed
Top-down by disease category:
overall gain in each category not
linked to specific intervention.
Attributed 20 to 30% of total
gain to R&D. Reduced morbidity
difficult to assess because little
reduction in days off work
because of sickness. Adjusted
the raw data, for example, by
applying historical Army and
Navy data as an index to record
the decline in sickness.
Top-down: overall gain in
mortality not linked to
specific interventions.
Attributed roughly one-third
of the total gain to R&D, plus
‘some fraction of the credit
for the other two-thirds.’
Top-down: overall gain
in mortality and morbidity
not linked to specific
interventions. Attributed
50% of the total gain to
R&D.
Top-down: as in the
2003 study, overall
gain in mortality and
morbidity not linked
to specific interventions.
Attributed 50% of the
total gain to R&D.
Bottom-up: identified
research-based
interventions, then
quantified health impact.
Top-down: overall gain
in mortality and morbidity
for five disease areas not
linked to specific
interventions. Attributed
50% of the total gain to
R&D.
How health gains
were valued
Human capital approach, that is,
values attached to lives saved
between one period and the
next, based on potential future
earnings, plus calculation of
value of potential working time
no longer lost due to sickness.
Used a comparatively high
‘willingness-to-pay’ value
derived from labour
economics.
Used the same
comparatively high
‘willingness-to-pay’ value
as Funding First.
Used a higher
‘willingness-to-pay’
estimate than the
2003 study, this time
derived from a
meta-analysis of
international studies.
Used a comparatively
low, but arguably realistic,
value of health gain by
adopting the figure
implied by the current
level of NHS spending,
that is, the opportunity
cost of a QALY within
the current NHS budget.
Used a lower
‘willingness-to-pay’
estimate than that used
in the 2008 study, in line
with Department of Finance
and Deregulation guidance.
Proportion of national
health gain allocated
to national research
Not discussed as a major issue;
we assumed it to be 100%.
Not discussed as a major
issue in Funding First; we
assumed it to be 100%.
Used proportion of global
research conducted in
Australia (2.5%) to
determine the proportion
of the total research-based
health gain to attribute to
Australian research.
Uses bibliometric
analysis-based estimate
of Australian share of
global research
output in clinical
medicine (3.04%).
An analysis of citations
of UK research on UK
clinical guidelines
suggests average best
estimate of 17% linked
to UK research.
Uses an updated
bibliometric analysis-based
estimate of Australian share
of global research output in
clinical medicine (3.14%).
Costs of health
care considered?
No, at least not as a separate
item to net-off against the
value of the health gains.
No in initial headline figures,
but Yes in later analysis: ‘the
gain in the value of life, net
what was spent to attain
the longer life, is just 15
percent smaller.’
No, did not net-off the
healthcare costs required
to achieve the health
gains.
No, did not net-off
the healthcare costs
required to achieve
the health gains.
Yes, did net-off the
health care costs required
to achieve the health gains.
Did not net-off health care
delivery costs, but did
consider avoided health
system expenditure due to
gains in wellbeing.
Considered elapsed
time between
research and health
gains?
Yes: 10 years. Acknowledged time lags
between research and
benefits but this was
apparently not brought
into calculations.
No, compared research
expenditure and health
benefits in the same year.
This implies the health gains
from research are instant.
Yes: 40 years, with range
of 20 to 60 years used
for sensitivity analyses.
Yes: an analysis of
citations of UK research
on UK clinical guidelines
suggested average best
estimate of 17 years lag.
Yes: same assumption of
40 years as was used in
2008 study. No sensitivity
analysis around elapsed
time.
How the overall rate
of return calculated
IRR of 47%. Not brought together to
provide an overall IRR.
An overall benefit/costs
ratio for health research
of 2.40.
An overall benefit/costs
ratio for health research
of 2.17.
IRR of 9% for CVD
research combined with
30% for GDP benefits.
Benefit-cost ratios for five
disease areas: 6.1 (CVD); 2.7
(cancer); 1.1 (SIDS); 1.2
(asthma); and 0.7
(muscular dystrophy).
Abbreviations: CVD cardiovascular disease, GDP Gross Domestic Product, IRR internal rate of return, NHS National Health Service, QALY quality adjusted life years, R&D research and development, SIDS Sudden Infant
Death Syndrome.
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2050. In doing so, they estimated the net benefit of
NHMRC R&D between 2000 and 2010 to be AU$1.96
billion with a cost/benefit ratio of 2.7; that is, for every
AU$1 million invested in cancer research they would
anticipate a return worth $1.7 million.
A recurring theme in these studies is the extent to
which health gains can be attributed to research-inspired
medical advances. Funding First and Access Economics
adopted a ‘top-down’ (or macro) approach that took a
measure of the overall national health gain from various
fields of medicine, and then assumed that a proportion
was attributable to medical research. One way of ad-
dressing this problem of attribution is by examining in a
bottom-up manner the impacts of specific projects or
programmes of research by tracing forwards from the
research to the benefits that arise. Here, considerable
progress has been made using the Payback Framework
[14-18], but this has relied on the development of specific
resource-intensive case studies. Other studies have made
progress in analysing the value of the health gains associ-
ated with a series of clinical trials [19], but the major chal-
lenge faced by these types of studies is attribution: that is,
how to show that the health gains that have arisen can be
attributed to specific pieces of research.
In 2008, we published a report, funded by the Wellcome
Trust and UK Medical Research Council, which aimed to
build on the advances in previous studies and address the
existing limitations, so as to develop an approach that
could be used to measure the economic benefits accruing
from publicly and charitably funded medical research [3].
We analysed two major elements of economic returns: the
broad impact on the UK Gross Domestic Product (GDP)
and the specific net monetary benefits (NMB), defined as
the health benefit valued in monetary terms minus the
cost of delivering that health benefit which arose from the
UK application of relevant UK research. Our analysis of
the existing evidence on the GDP or ‘spillover’ benefits,
based largely on US studies from a number of areas of
research and certainly not specific to any particular area
of medical research, suggested a best estimate of an in-
ternal rate of return (IRR) of around 30%. We estimated
the NMB of the health gain using methods similar to
those used here, giving an IRR of 9% for cardiovascular
research. This meant that a GB£1.00 investment in publicly/
charitably funded CVD research produced a combined
stream of benefits thereafter, equivalent in value to earn-
ing £0.39 per year in perpetuity. (We also estimated the
NMB from mental health research, which produced an
IRR of 7%; however, this was based on a more limited ana-
lysis because of data limitation and uncertainties around
the effects of interventions in mental health, which meant
that we were less confident in the results than we were for
the CVD results).These estimates of the IRR have been widely used in
policy circles in the UK and beyond [20-23], and in the
absence of any other estimates of the economic impact
of biomedical research, the figures have often been used
as proxies of the economic impact of medical research
more broadly. A consortium of funders (Wellcome Trust,
National Institute of Health Research, Cancer Research
UK (CRUK), and the Academy of Medical Sciences)
commissioned a study to further validate the approach
and to explore whether the IRR from the net value of
the health benefits in another area, cancer, was similar
or not. Thus, this study aimed to estimate the economic
returns from UK publicly and charitably funded cancer
research on improved health outcomes in the UK specific-
ally. As with the previous CVD study, we accept that there
are international benefits of UK research, but this was not
in the scope of the current exercise, although as we note,
this is an area that warrants further investigation. In
addition, and as reported separately [24], we undertook
five exploratory case studies to understand qualitatively
the complexity of how research translates into health
benefit.
We present the methods used for the four main steps
that provided the estimated parameters to enable us to
calculate the economic returns from the NMB of the UK
health gains that we attributed to past UK publicly and
charitably funded cancer-related research, and present
the results expressed as estimates of the IRR, with sensi-
tivity analyses to illustrate the effects of some of the key
uncertainties. Finally, we explored the significance of our
findings in the context of previous studies and the wider
policy debate on R&D investments and economic impact;
we detailed the limitations of our approach; and we devel-
oped a research agenda for this fledgling field.
Methods
Overall conceptual approach
Four key sources of data were needed to estimate the
IRR of the NMB of the health gains arising from cancer
research:
 a time series of the public and charitable funding of
cancer-related research;
 a time series of the NMB of cancer health gains,
derived from the monetised health benefits and
the healthcare costs for selected interventionsa;
 an estimate of the elapsed time between the
investment (research funding) and return
(health gain) associated with those
interventions; and
 an estimate of the amount of health gain that
should be attributed to public and charitable
research investment in cancer-related research
in the UK.
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of return on the investment in cancer research.
It should be noted that the costs of private sector
R&D investments are accounted for in our analysis as
elements within the cost of delivering health care, which
are netted off in the NMB. The costs to the health
service of medical interventions produced by the private
sector include the return to the private sector on its
R&D investments.
Estimating public and charitable funding of cancer-related
research
The leading funders of cancer research in the UK were
identified by examining the National Cancer Research
Institute (NCRI) Cancer Research Database. Between
2002 and 2011, the top 10 funders consistently accounted
for over 95% of cancer research spend by the 21 NCRI
partners.b Estimates of annual cancer-related research
funding between 1970 and 2009 were assembled for these
10 organisations plus an estimated contribution to cover
Funding Council support for cancer research (the Higher
Education Funding Council for England and similar bod-
ies in Wales, Scotland and Northern Ireland provide a
performance-related block grant to UK universities based
on the quality and volume of research). A detailed account
of how we estimated these 11 time series is provided (see
Additional file 1).
As also discussed in detail in Additional file 1, in esti-
mating research spend for the Funding Councils and the
Department of Health (DH)/NHS, we had to derive a
figure specifically for cancer-related research activity in
the UK. We settled on a central estimate of 10% of total
publicly and charitably funded health and biomedical
research activity, and we also assumed it to be constant
over the time period. This estimate was derived from a
number of independent sources, as follows
 Medical Research Council (MRC) spending on
cancer research averaged 9.8% of their total
investment (range: 4.6% to 16.7%) between 1970/1
and 2009/10.
 Wellcome Trust cancer funding was more erratic,
ranging between 1%c and 38%, with an average of
14.5% of expenditure being on cancer research.
 The proportion of peer-reviewed research papers in
oncology as a percentage of all UK biomedical
outputs averaged 9.2% (range: 8.5% to 9.5%) between
1988 and 1995 [25].
 The proportion of peer-reviewed research papers in
oncology research (as a percentage of all NHS
research outputs) was 12% between 1990 and
1997 [26]. The proportion of mainstream quality-related (QR)
funding allocations by the Higher Education FundingCouncil for England for ‘Cancer studies’ (that is,
Unit of Assessment 02) between 2009 and 2012 was
around 6% of the total biomedical allocation (that is,
Unit of Assessments 01 to 15 and 44).d
Given the importance of this estimate of 10% for the
proportion of research activity that is related to cancer
(for those sources where we had no actual breakdown),
we also looked at the effect of lower and higher estimates
of 7.5% and 15%, respectively, in the sensitivity analyses.
Estimating the NMB from cancer-related research
This element of the research required estimates of the
lifetime QALYs gained and the net lifetime costs to the
NHS of delivering those QALYs for research-based inter-
ventions provided in each year of the period 1991 to
2010. The general methods mirrored those used in the
2008 study [3] on the returns on investment in CVD
research, and again built up the aggregate net benefits
from the bottom up, aggregating the QALYs gained and
the net NHS costs from the use of specific interventions.
This approach required: 1) identification of the key rele-
vant cancer interventions and their level of usage during
the relevant period; and 2) estimates of the QALY gains
and NHS costs associated with the interventions. From
this information, the NMB was calculated as the health
benefit valued in monetary terms (determined by the
quantity of health benefit and a decision-maker’s will-
ingness to pay for that additional benefit) minus the cost
of delivering that health benefit.
In the CVD study, our starting point was previously
published research identifying the cardiovascular inter-
ventions that had contributed most health gain [27]. No
equivalent studies for cancer were identified that could
provide a comparable basis for deciding which interven-
tions were, quantitatively, the most important to include
in the analysis. Thus, the three main steps for quantify-
ing the total NMB associated with cancer interventions
were: 1) to identify the cancer interventions that were the
likely major sources of benefits; 2) to identify appropriate
estimates of NMB per patient for that subset of cancer
interventions; and 3) to construct a time series (for 1991
to 2010) of the number of patients receiving each of these
subsets of cancer intervention in the UK.
Identifying the key cancer interventions
At the outset of the study, we had a number of discussions
with cancer research experts to provide us with a broad
understanding of the main developments in the field over
the past 20 years. Informed by these discussions, we
quantitatively identified those areas that had resulted in
the largest health gain in the UK since 1990, arising
from three main sources: 1) key cancers where research
and resultant health policies have led to health gains
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which screening programmes have led to health gains
because of early detection; and 3) key cancers where
there have been the most significant health gains from
increased survival.
To identify areas where a reduction in incidence has
been observed, cancer incidence data in the UK were
analysed, using UK incidence rates between 1990 and
2008 [28], to calculate a percentage change over the
period. This percentage change was then multiplied by
mid-period UK incidence (the average per year for 1999
to 2001 [29]) to estimate an absolute change in incidence.
Four cancer types have seen significantly larger reductions
in incidence between 1990 and 2008: lung (6,500), stom-
ach (4,400), bladder (4,400), and cervical (1,400) cancers.
Additional file 2 gives full details for the 21 cancers. The
literature was consulted to identify possible causes for
these reductions in incidence. Overwhelmingly, smoking
prevention and cessation was cited as the reason for a
reduction in lung cancers [30]. Falls in rates of stomach
cancer are also thought to be linked to smoking along
with declines in Helicobacter pylori and improvements in
diet [29,31]. The picture is less clear, given changes in the
ways these cancers are coded, but bladder cancer has been
shown to be associated with smoking too [32], which may
account for the decline in rates. The fall in cervical cancer
can be largely attributed to the roll-out of cervical
screening since the 1980s, which in addition to detecting
cancers, is able to pick up pre-cancerous abnormalities
and so reduce the incidence of cancer. This has led to a
focus on reduction in smoking and on cervical screening.
In addition to cervical screening (which has been in its
present form since 1988), there are currently two other
national screening programmes in the UK aimed at early
detection of cancers: breast cancer screening (introduced
in 1988) and colorectal cancer screening (introduced in
2006). There is evidence that all three programmes have
reduced mortality [33-35], and should be included in
our list of priority interventions.
There have been substantial advances in cancer treat-
ment in recent decades, which have led to valuable health
gains. Surgical techniques remain a cornerstone of treat-
ment, aided by ever-refined radiotherapy methods. The
advent of new cytotoxic therapies, as well as hormonal
and biological therapies, has greatly increased the available
treatment options. Given the breadth of these treatments
(and backed up by the number of treatments that expert
opinion had identified) it was necessary to limit the focus
of our estimation to a subset, which we expected to in-
clude most of the health gains likely to have been ob-
served between 1991 and 2010. Data on changes in
survival were used as a proxy for health gains. Data
were compiled for cancer types on 1-year and 5-year
survival rates from CRUK [36] and the Office for NationalStatistics (ONS) [37] (see Additional file 2). Rates were
calculated as percentages for the period 1986 to 1990, and
compared with those in 2005 to 2009 to calculate a
change in the proportion of people surviving 1 and
5 years after diagnosis. This change in rate was then
multiplied by the ‘mid-point’ incidence in 1999 to 2001
to estimate the additional number of people surviving.
The same three cancer types (albeit in slightly different
order) were found to have the highest number of additional
people surviving for both 1 and 5 years; these were pros-
tate, colorectal, and breast cancer. These three accounted
for 73% of the estimated gains in 5-year survival. Using
clinical guidelines published by the National Institute for
Health and Care Excellence (NICE) a set of the main inter-
ventions for each of these three cancer types was identified.
These interventions were all treatments, because, although
there have been improvements in diagnostics and service
configuration, it was assumed that the benefits derived
from these should, in principle at least, be reflected in the
number of people accessing treatment and in measures of
treatment effectiveness.
Identifying estimates of per-patient NMB for the set of
cancer interventions
As a result of the approach outlined above, estimates of
per patient cost and effects were then obtained from
published studies for the following prioritised areas:
 Smoking prevention/cessation
 Screening programmes: cervical, breast, and bowel cancer.
 Treatment of: breast, colorectal and prostate cancer.
Smoking prevention/cessation
The area where we adopted a very different approach to
that which we had previously used for CVD was smoking.
In that study, we restricted the analysis to the costs and
benefits arising from NHS smoking cessation interventions.
Cancer research has not only unequivocally shown the
causal link between smoking (both active and passive) and
both cancer and the risks of cancer (and other health
problems) but also the effectiveness of various national
interventions in reducing smoking rates. This cumulative
evidence has contributed to a slow but steady change in
smoking behaviour both through direct effects on indivi-
dual behaviours and through the many non-NHS interven-
tions in the UK (such as legislation and taxation) which
have followed from, and been made possible by, this evi-
dence, and have encouraged existing smokers to quit and
discouraged others from taking up smoking, as summarised
in Figure 1. Therefore, health gains from research include
not only the benefit from getting smokers to quit (aided or
not by the NHS), but also in preventing non-smokers
from ever starting smoking. A recent modelling study
for the UK DH Policy Research Programme provided
estimates of lifetime life years gained and cost savings
era
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with smokers [38]. The model accounted for the mor-
tality benefits from not smoking associated with lung
cancer, myocardial infarction, stroke, and chronic ob-
structive pulmonary disease. In the absence of age-
specific smoking rates, we used the estimates for men
and women aged 35 years, and adjusted these to take ac-
count of the proportion of life years gained resulting
from lung cancer reduction and also the adjusted life
years gained by the population mean utility values for the
relevant ages in order to estimate QALYs gained [39].Figure 1 Smoking behaviour in England, 1982 to 2010. Source: Gen
Copyright © 2012, re-used with the permission of The Office for NationaScreening programmes
To estimate the NMB of each of the three screening
programmes, we identified the most appropriate eco-
nomic evaluations that modelled the lifetime costs and
effectiveness of offering the screening programmes as
delivered in the UK. For both cervical and bowel cancer
screening we used assessments that had informed rele-
vant screening policy decisions [40,41]. In the case of
cervical screening, we adjusted the figures presented as
life years gained by an appropriate age/sex population
utility values to give an estimate of QALYs [39]. For
breast cancer, we used a recently published economic
evaluation that had used a life-table model to assess the
overall cost-effectiveness of the NHS screening programme
which based its assessment of effectiveness on the findings
of the Independent UK Panel on Breast Cancer Screening,
and took account of the uncertainty of associated estimates
of benefits, harms, and costs [33,42]. In all three cases,
these models used take-up rates that were the same or
very similar to those observed in the relevant screening
programme during the period in question.Treatment programmes
The full list of treatment interventions included in the esti-
mation of health gains for each cancer site are shown in
Additional file 3. These were determined based on NICE Cli-
nical Guidelines (CG131 for colorectal cancer [43], CG80 and
CG81 for breast cancer [44,45] and CG58 for prostate cancer
[46]) and cross-checked to ensure that relevant interventions
identified by experts were included. Patient sub-groups were
recognised where distinction in treatments was made, or
where likely differences in cost and benefits existed. In breast
cancer, for instance, this distinction was made for node-
positive cancers, oestrogen receptor-positive cancers, HER-2-
expressing cancers, and pre/post-menopausal incidence of
cancers, and between early-stage and late-stage cancer. Histo-
l Lifestyle Survey 2010. The Office for National Statistics.
tatistics.rical comparators for each intervention identified from the
contemporary guidelines were then identified back to 1991.
For each of the treatment options considered, published
economic evaluations were used to estimate per patient
costs and benefits (measured as QALYs). Searches were
conducted using the NHS Economic Evaluation Database
and MEDLINE to identify economic evaluations of pros-
tate, breast, and colorectal cancer interventions. UK-
specific estimates were preferred, but international evidence
was used where no appropriate UK estimates were avail-
able. Where they were available, NICE technology ap-
praisals and National Institute of Health (NIHR) Health
Technology Assessments were used as the most relevant
sources (see Additional file 3). Where exceptionally non-
UK cost-effectiveness data had to be used, costs were con-
verted using purchasing power parity exchange rates.
Constructing a time series (1991 to 2010) of usage of
cancer interventions
To estimate total NMB for the period, per-patient QALY
gains and net costs for each intervention were multiplied
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vention in each year. We used the following methods to
estimate the time series of usage for the selected
interventions.
For smoking reduction/cessation we used figures derived
from the data on the proportions of smokers, ex-smokers
and non-smokers for England for each of the years to
estimate the net change per year in QALYs gained and
NHS savings achieved, and related these to population
data for the UK as a whole [47].
For cervical and breast screening programmes, we used
figures for the relevant size of the UK age group in each
year to whom screening was first offered (age 25 for cer-
vical and age 50 for breast). For bowel screening we used
the numbers first offered screening as the programme
began to be rolled out.
To estimate the numbers of people receiving each
treatment intervention over time two primary sources
were used. For surgical procedures (for example, colo-
rectal excision, liver resection and ablation, prostatectomy,
orchiectomy, mastectomy and lumpectomy) Hospital
Episodes Statistics [48] were utilised. To estimate the
numbers of people receiving drug interventions, data on
Net Ingredient Cost (NIC) of drugs to the NHS were
used. These data were gathered from Health and Social
Care Information Centre (HSCIC) data publications
[49], which give details of the total cost of a particular
drug prescribed in primary care (for the Prescription
Cost Analysis) and secondary care (Hospital Prescriptions
Audit Index) in each year. For some drugs, this informa-
tion was not available for the whole of the time period, in
which case assumptions were made on the basis of launch
year and the most recent available time point. If the
launch year occurred during the period 1991 to 2010, a
linear interpolation with launch year at £0 NIC was per-
formed. For drugs that were not launched during the
period, a last value carried back approach was adopted,
using the most recent year of historical data. From the
NIC, the cost and length of a typical regimen (as esti-
mated by NICE costing templates where possible) were
used to calculate the number of complete treatments
delivered and hence the number of people receiving a
particular drug in any given year. This was then propor-
tioned across the indications of a drug and particular
patient group (for example, early and late cancers, or
multiple cancers).
For some older drug interventions, NIC data were not
publicly available for any of the years of interest. In these
instances, NICE estimates of the proportion of patients
likely to receive interventions (based on guidance costing
templates) were combined with data on incidence to esti-
mate usage numbers.
For radiotherapy, there was a paucity of data on usage.
Data from the National Clinical Analysis and SpecialisedApplications Team (NATCANSAT) were available for
2009/10, giving the number of episodes of radiotherapy.e
It was estimated that 70% of these episodes would be for
primary treatment of a cancer. The number of primary
radiotherapy episodes was estimated as a proportion of
the incidence of each cancer in 2009/10. This proportion
was applied historically to incidence in order to estimate
radiotherapy treatment.
The component figures of numbers of people receiving
treatment interventions were all derived from data for
England. To produce a UK estimate (needed because the
research spend data is for the UK) figures were adjusted
by a factor reflecting England’s proportion of the adult
UK population. The screening was based directly on
relevant UK population data, and for smoking behaviour
the time series data were for England, but have been
applied to the UK population. All cost estimates were
adjusted to 2011/12 prices using the Hospital and
Community Health Services Pay and Prices Index [50].
For the calculation of NMB, we used for the base case
an opportunity cost value of a QALY as used by NICE in
its decision-making [51,52]. This value reflects an estimate
of the opportunity cost in terms of QALYs forgone else-
where in the health service within its fixed budget. Given
that public spending on health research can justifiably be
seen as a decision to spend on research rather than dir-
ectly on current healthcare, this opportunity cost value
is appropriate to the public decision regarding research
funding. In this study, as previously for CVD, we char-
acterised NICE’s threshold range as equivalent to an
average of £25,000 per QALY, but considered a broader
range of values in the sensitivity analysis, including a
value of £70,000, which would be broadly consistent
with the commonly proposed QALY threshold of 3 times
GDP per capita [53].
Analysis of UK clinical guidelines to estimate elapsed time
and rate of attribution
In the 2008 report on CVD research, the references cited
in a sample of clinical guidelines were analysed to inform
the estimate of the elapsed time between research spend
and net health gain, and the proportion of net health gain
that could be attributed to UK research [3]. In the current
study on cancer research, we replicated this approach.
In total, 31 national clinical guidelines, which provided
a broad representation of cancer practice in the UK,
were identified. Twelve were published by NICE and a
further twelve by the Scottish Intercollegiate Guideline
Network (SIGN). The remaining seven guidelines were
published by either the Royal Colleges or the National
Cancer Screening Programme. The reference sections of
these guidelines were reviewed: five had no reference list
(four published by NICE, one by the National Screening
Programme) while one screening guideline had no
Glover et al. BMC Medicine Page 9 of 202014, 12:99
http://www.biomedcentral.com/1741-7015/12/99references to peer-review journals (that is, it referenced
only policy and practice documents). These six guidelines
were excluded from our sample. We then used a bespoke
computer programme to extract references from the elec-
tronic PDF version of each guideline; in three cases the
automated reference extraction failed (because papers
were not referenced in a recognised format), leaving us
with a sample of 22 national guidelines.
Of the 5,627 references cited in the 22 guidelines, 4,416
references (78%) were automatically extracted, excluding
duplicate references within a guideline (see Additional
file 4 for breakdown by guideline). Nine of these refer-
ences had no date information and were excluded from
the analysis of elapsed time, leaving a total of 4,407 ref-
erences. The age of a paper cited in a clinical guideline
has been termed the ‘knowledge cycle time’ [54], which
is the average difference between the publication date
of the clinical guideline and the publication date of the
cited papers on the guideline. The knowledge cycle time
was calculated for the 22 identified guidelines, and used to
inform the estimated elapsed time.
To estimate the rate of attribution to the UK, the 4,416
extracted and de-duplicated references were provided to
the Centre for Science and Technology Studies (CWTS)
to be matched to their bibliometric database (which is de-
rived from the Web of Science).f Of the 4,416 extracted
references, CWTS was able to match 4,051 (92%), which
formed the dataset to estimate the degree of attribution
based on the address field in the cited papers. These ad-
dresses were used as a proxy for the location in which the
research was conducted, and so it was possible to estimate
the proportion of the cited research that was conducted in
the UK. The non-matched references included non-serial
outputs such as books, journals that are not indexed on
the Web of Science, and incorrect references.
Estimation of the rate of return
Using these four key sources of data, we could then
attribute a proportion of the estimated total annual NMB
of the cancer health gain as being due to UK research, and
relate an equal number of years of investment to years of
NMB, ‘lagged’ by an estimate of the average lag between
research and benefit. The return was expressed as an IRR,
which is effectively the discount rate that would yield a
zero net present value. The IRR is convenient in enabling
a comparison to be made between non-competing in-
vestments of different sizes (as well as providing a dir-
ect comparison with our previous study). We recognise
the many and various layers of estimates involved. In
other circumstances, it might be feasible to express the
uncertainty as ranges for each parameter in our overall
estimate and undertake a formal probabilistic sensitivity
analysis (PSA). However, given the nature of the evidence
from multiple sources for the numerous parameters andthe necessary judgments involved in drawing together and
interpreting the evidence, a comprehensive PSA quantita-
tively characterising all the uncertainty was not feasible
here, and indeed would be liable to suggest a spurious
precision. Instead we provide a series of one-way and
scenario sensitivity analyses to illustrate the effects of
specific variables on the IRR.
Results
Public and charitable funding of UK cancer-related
research, 1970 to 2011
Additional file 1 provides our estimated expenditure by
year by organisation for the 40-year period, 1970 to 2009,
with a summary of cash expenditure provided in Figure 2.
Figure 3 illustrates estimated public and charitable ex-
penditure on cancer-related research from 1970 to 2009
in cash and constant 2011/12 prices (the latter for our
best estimate). About £15 billion (in 2011/12 pricesg) of
cancer-related research funding was invested during this
period. The data presented in Figure 3 are derived from a
number of different sources and include various assump-
tions and estimations. For this reason, we also provided a
‘high’ and ‘low’ scenario for total cancer-related research
expenditure with a range of £14 to £17 billion. In Figure 3,
we also present total public and charitable spending on
cancer-related research in cash terms. This emphasises
that in real terms (in 2011 prices; the red line) spending
fell between 1970 and 1979, then stagnated until 1986,
and thereafter increased threefold, from £250 to £850 mil-
lion, by the end of the time series in 2009.
Net monetary benefit
Table 2 shows the contributions to our total estimates of
lifetime QALYs gained from the seven areas we addressed,
classified by the year in which the intervention was deliv-
ered (or in the case of screening, the year in which those
targeted entered the screening programme). Reduction in
smoking accounted for 51% of the QALYs gained from the
seven areas we prioritised. The other two large sources of
QALYs gained were from cervical screening (21%) and
breast cancer treatments (19%). The other areas we exam-
ined were small contributors by comparison.
Table 3 shows the lifetime net costs to the NHS for
each of these areas over the 20-year period. The key
points to note here are the high proportion of total net
costs accounted for by breast cancer and prostate cancer
treatments. Smoking reduction on the other hand reduces
net NHS costs, as does colorectal screening, although the
latter’s introduction late in the period covered means its
absolute contribution to reducing overall costs is small.
Table 4 summarises the NMB when the QALYs have
been valued at £25,000 and the net costs to the NHS of
the intervention and its long-term sequelae have been
deducted. It shows how the total NMB (when measured
Figure 2 Total estimated public and charitable spend on cancer research by source of funding, 1970 to 2009, in current (cash) prices.
Glover et al. BMC Medicine Page 10 of 202014, 12:99
http://www.biomedcentral.com/1741-7015/12/99in constant prices) from the research-based interven-
tions that we have assessed has been steadily increasing,
with an overall increase of 28% over the 20-year period.
Over the whole period, smoking reduction (providing
for both QALYs and NHS cost savings) accounted for
65% of NMB, followed by cervical screening (24%) and
breast cancer treatments (10%). All seven areas we studied
showed a positive NMB when QALYs were valued at
£25,000. However, at a QALY value of £20,000, prostate
Figure 3 Public and charitable funding of cancer research 1970 to 20
current (cash) prices.and colorectal treatments and breast cancer screening all
showed a negative NMB (that is, their net costs exceeded
the valuation of the benefits they provide).
Estimating the elapsed time
The estimate of the elapsed time used in the study was
based primarily on the analysis of cited references on
clinical guidelines (that is, knowledge cycle time). As
illustrated in Figure 4, the mean age of the 4,407 cited
09, at constant (2011) prices with low and high estimates, and in
ate
Ys
rv
1992 9 48 6
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1994 11 48 6
1995 10 45 6
1996 11 46 6
1997 11 46 6
1998 11 50 6
1999 13 53 7
2000 15 53 7
2001 17 55 7
2002 20 56 8
2003 22 59 8
2004 24 61 9Table 2 Contributions of the seven areas to the total estim
QAL
Year Treatment
Prostate cancer Breast cancer Colorectal cancer Ce
1991 8 46 6papers on the 22 guidelines was 8 years, ranging from 0 to
88 years (the median age was 6 years, with an interquartile
range of 3 to 10 years). To produce an estimate of elapsed
time between spending on research and health gain as
required for this study, it was necessary to add on to this
value the estimates for the period between the awarding
of funding and publication, and the period between rec-
ommendation and use. Using the same approach adopted
in the 2008 report, we estimated these two periods to total
approximately 7 years, giving a best estimated elapsed time
between spending on research and health gain of 15 years,
with 10 and 20 years arbitrarily selected as lower and higher
estimates for sensitivity analyses.
Estimating the amount of health gains that can be
attributed to UK research
The estimate of the proportion of the health gain that
can be attributed to UK research used in the study was
based primarily on the analysis of cited references on
clinical guidelines. A total of 4,051 publications were ana-
lysed to estimate the proportion of the research that could
be attributed to the UK. The overall percentage across all
2005 21 62 10
2006 22 62 12
2007 23 65 13
2008 27 68 14
2009 26 71 15
2010 25 74 15
Total 339 1112 173
Abbreviation: QALY quality adjusted life year.s of lifetime QALYs gained by year: 1991 to 2010
(thousands)
Screening Smoking
reduction
Total
ical cancer Bowel cancer Breast cancer
71 – 2 144 277
70 – 2 144 279
68 – 2 145 276
67 – 2 145 279
65 – 2 145 273
66 – 2 146 276
63 – 3 146 274
59 – 2 147 276
56 – 2 147 279
55 – 2 148 281
54 – 2 149 285
53 – 2 150 290
53 – 2 151 295
56 – 2 152 305guidelines was 17%, but as shown in Additional file 4, this
differed between specific guidelines.
Estimating the IRR from cancer-related research
Our estimates of the NMB produced by year (summarised
in Table 4) were then related to the estimated public and
charitable spend by year on cancer-related research (sum-
marised in Figure 3) and expressed as an IRR. Calculation
of the IRR incorporates our best estimates of the elapsed
time of 15 years (low and high estimates of 10 and
20 years) and of the proportion of the NMB that could
be attributable to UK research (best estimate 17%: low
and high range estimates of 10 and 25%). Thus in our
base-case calculation we related 17% of the annual
NMB (for each of the 20 years 1991 to 2010) to 20 years
of the research investment that had occurred 15 years
earlier (that is, for the years 1976 to 1995; in other words,
a subset of the 1971 to 2009 series collated). This pro-
duced a base-case estimate of the IRR of 10.1%.
As is evident from the methods used, there is inevitably
considerable uncertainty around the values of all our
estimates. Table 5 presents a series of one-way sensitiv-
ity analyses to illustrate the effects of some of the main
60 – 2 154 309
61 2 2 155 316
60 5 2 157 324
60 7 2 158 337
63 9 2 159 345
65 12 3 161 354
1225 35 43 3003 5930
fs (
rv
Glover et al. BMC Medicine Page 12 of 202014, 12:99
http://www.biomedcentral.com/1741-7015/12/99Table 3 Contributions of the seven areas to the estimates o
1991 to 2010
Cost
Year Treatment
Prostate cancer Breast cancer Colorectal cancer Ce
1991 199 665 181
1992 220 687 190
1993 241 658 185
1994 272 684 185
1995 252 646 175
1996 278 660 182
1997 269 684 181
1998 283 720 187
1999 336 753 214
2000 391 746 211
2001 456 755 206
2002 519 764 202areas of uncertainty, and all changes have predictable
effects. For NMB, the greatest uncertainty in our calcula-
tions probably relates to the magnitude of the benefits
from smoking, given the indirect nature of the estimate.
Reducing (or increasing) the NMB from smoking by 25%
produced an IRR of 8.7% (or 11.2%); for illustration, the
(unrealistic) extreme of removing entirely the benefits
from smoking from our estimates produced an IRR of
2.4%. The IRR increased as our estimates of research
funding were reduced, and the proportion of benefits
attributable to UK research increased. It was found to
be particularly sensitive to a reduction in the elapsed
time. Although taken individually, all of the alternative
values we have explored in this sensitivity analysis showed
a reasonable rate of return, in combination they could
of course have produced a wider range of estimates for
the IRR.
Discussion
Taking into account the necessary assumptions made in
our approach, the base-case IRR for the NMB from the
2003 571 794 178
2004 614 817 179
2005 545 850 182
2006 572 851 188
2007 596 881 177
2008 613 919 181
2009 606 950 185
2010 569 986 186
Total 8403 15469 3755
Abbreviation: NHS National Health Service.lifetime costs to the NHS of services delivered by year:
GB£ million)
Screening Smoking
reduction
Total
ical cancer Bowel cancer Breast cancer
41 – 34 -277 844
40 – 37 -277 897
39 – 40 -278 887
39 – 42 -278 944
37 – 42 -279 874
38 – 43 -280 921
36 – 53 -281 943
34 – 50 -282 993
32 – 47 -283 1098
32 – 45 -285 1140
31 – 43 -287 1204
30 – 43 -282 1276health gain from cancer research of approximately 10%
is remarkably similar to that derived for CVD research,
where the IRR derived from the health gain was 9%. These
benefits alone provide a return considerably greater than
the UK government’s minimum threshold of 3.5% for
investments, thus suggesting that investment in cancer
research is worthwhile. Moreover, given that CVD, cancer,
and mental health account for about 45% of the total bur-
den of disease in the UK [55], we might with increasing
confidence extrapolate this order of rates of return to the
whole of the public and charitable investments in biomed-
ical and health research in the UK. The important caveat
to that statement is that the two of the clinical areas that
we have analysed in most detail – cancer and CVD –have
both benefitted significantly from the changes in smoking
over the period analysed.
However, it should be remembered that in our previous
study, the rate of return from NMBs of the health gain
was less than a third of the rate of return (30%) that we
suggested might relate to the broader GDP gains. If we
accept that estimate of returns from GDP, then again the
30 – 44 -255 1361
32 – 44 -254 1432
34 – 44 -252 1403
35 -5 45 -258 1428
35 -10 46 -252 1473
35 -15 48 -242 1538
36 -20 48 -237 1569
38 -25 56 -240 1569
704 -75 894 -5358 23793
Table 4 Contribution of the seven areas to the estimates of net monetary benefit by year: 1991 to 2010 (QALY value
of £25,000)
Net monetary benefit (£ million)
Year Treatment Screening Smoking
reduction
Total
Prostate cancer Breast cancer Colorectal cancer Cervical cancer Bowel cancer Breast cancer
1991 8 490 -33 1729 – 7 3885 6085
1992 8 506 -35 1699 – 7 3889 6075
1993 9 485 -33 1659 – 8 3890 6018
1994 10 504 -32 1646 – 8 3894 6030
1995 9 475 -28 1592 – 8 3906 5963
1996 -3 483 -28 1609 – 9 3920 5989
1997 -3 458 -28 1546 – 11 3933 5916
1998 -3 531 -29 1447 – 10 3947 5902
1999 -10 566 -40 1374 – 9 3966 5866
2000 -15 579 -36 1350 – 9 3989 5876
2001 -25 630 -30 1310 – 9 4018 5910
2002 -8 647 -5 1283 – 9 4037 5963
2003 -14 677 24 1294 – 9 4035 6025
2004 -7 705 49 1376 – 9 4064 6195
2005 -15 694 67 1460 – 9 4099 6314
2006 -16 697 106 1484 64 9 4138 6481
2007 -23 736 149 1469 128 9 4167 6635
2008 51 786 171 1474 192 10 4192 6876
2009 46 816 178 1528 256 10 4216 7050
2010 66 854 183 1596 320 11 4253 7282
Total 65 12318 566 29927 960 179 80437 124452
Abbreviation: QALY quality adjusted life year.
Figure 4 Age of papers cited on cancer clinical guidelines.
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Analysis IRR, %
Base casea 10.1
Research funding estimate
Low 10.8
High 8.7
‘Value’ of a QALY, GB£
20,000 8.0
30,000 11.7
50,000 16.1
70,000 18.9
Elapsed time, years
10 14.6
20 7.4
Attribution to UK research, %
10 6.1
25 13.0
Effect of smoking cessation
Decrease NMB by 25% 8.7
Increase NMB by 25% 11.2
Omitting benefit of smoking reduction 2.4overall returns from cancer research would be in the order
of 40%. However, as we noted then, although this estimate
was based on the best available information, it was
generated from a small empirical literature, much of it
US-centred and only a proportion specific to medical
research. From the papers reviewed, a rate of return
between 20% and 67% was identified and we took 30%
as our ‘best estimate’. The current study did not revisit
this aspect of the return to investment. As discussed
below, we recommend that future research should aim
to update and improve on these estimates.
What this paper contributes
In this study, our main methodological contribution was
to further validate the bottom-up approach we developed
in the original Medical Research: What’s it Worth? study
[3]. This new application strengthens our argument that
the bottom-up approach represents a significant improve-
ment on earlier attempts to estimate economic returns
from research, as it attempts to directly attribute health
gains (as measured by QALYs) to research-derived inter-
ventions. The alternative ‘top-down’ approaches face the
fundamental problem of starting with changes in mortality
or morbidity over time, and attributing an estimated
proportion of these changes to biomedical and health
research. In addition, and in line with our previous
Abbreviations: IRR internal rate of return, NMB net monetary benefits, QALY
quality adjusted life year.
aBest estimate for research funding and net monetary benefit, QALY value of
£25,000, elapsed time of 15 years, and attribution to UK research of 17%).work, we have taken into account the costs of delivering
the health gain and the elapsed time between research
investment and health gain, which earlier studies had
largely failed to do.
Key assumptions and caveats
Despite validating and further developing the approach,
there are still a number of key assumptions and caveats
in our estimate of the economic returns from cancer-
related research. Given this, we would be the first to
acknowledge that the bottom-up approach by necessity
relies on these assumptions, and that our findings do
need to be treated with appropriate caution. We docu-
ment these assumptions in the interests of transparency,
and to stimulate further research. The key assumptions
are as follows.
 Our base-case value of a QALY is £25,000.
Obviously, and as demonstrated by our sensitivity
analysis, the IRR is sensitive to the assumed value of
the health gain measured as QALYs. Our base-case
assumption is consistent with our analysis of the
returns to CVD research, and reflects the mid-point
in the range of values (of £20,000 to £30,000) cited as
the normal criteria for acceptance of interventions by
NICE [51]. More recently, NICE has increased this
threshold, up to around £50,000, for certain treatments
that provide end-of-life benefits, particularly late-stage
cancer treatments [52]. At the same time it has seemed
to re-emphasise that the £20,000 threshold should
apply unless there are special circumstances. Although
this leaves uncertainty about the most appropriate
value here (as reflected in our sensitivity analysis),
conceptually the argument remains that this
‘opportunity cost’ value of a QALY should apply to
an assessment of research in that investing in
health-related research can be seen as an alternative
to spending the money directly on current health
care. We note, however, that other studies in the US
and Australia have used much higher values, reflecting
individual willingness to pay for health gains, and
we have illustrated in a sensitivity analysis the effect
of using a value of the order of three times GDP per
capita [53].
 The total NMB for interventions not covered is
assumed to be zero. Our IRR calculation assumes
that all other cancer treatment developments/
interventions that we have not specifically included
have, in aggregate, no effect on the NMB, because
for these, the monetised value of the health benefit
is equal to the cost of delivering the benefit.
In reality, there may be some areas that we have not
covered for which the NMB is negative because of
the high cost of treatment and low incremental
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areas that generate a significant number of QALYs
at a relatively low cost. We are not in a position to
know whether the net effect of the interventions we
did not examine is positive, negative, or zero.
 The total net flow of knowledge between
disciplines is zero. We have assumed that the flow
of knowledge is the same into and out of different
research fields, and from each research field into the
cognate treatment areas. However, we know that
research is unpredictable and diffuse, and there may
be research disciplines that contribute more than
they gain from other areas. One could argue that
some of the reduction in mortality from diseases
other than cancer that arises as a result of the
reduction in smoking (e.g. CVD) which we have
excluded, should in fact be included as having been
achieved as an additional advantage arising from the
evidence of the effect of smoking on lung cancer.
 All health gain from treatments is captured in the
estimates of the health gain from specific
interventions. We have assumed that in principle
the health gain from improved service configuration
and all other supportive service changes (including
diagnostics and imaging) should be captured in the
estimates of the gains from specific interventions. In
practice, our estimates of QALY gains are mainly
derived from UK-relevant health technology
assessments that are extrapolated from trial data,
which may provide an imperfect estimate of the
gain when the interventions are used in routine
NHS practice.
 The definitions of the cancer-related research used
by the research funders captures basic research
that may have contributed to developments in this
area. This is clearly the case for the cancer-specific
funders such as CRUK, as we included all the research
they funded. For MRC funding, we relied on the
funder classification which, as discussed in Additional
file 1, was broad and thus should include basic re-
search. For the Wellcome Trust, which accounts for
around 10% of total cancer funding, we had to rely on
search terms. We scanned the list of grant titles se-
lected through this search strategy, and this list sug-
gests that fundamental research is being included,
although we cannot guarantee that it all is in fact in-
cluded. For the remaining two funders – the Funding
Councils and the DH/NHS – this would not be an
issue, as their time series were derived through an es-
timate of cancer research activity.
 The knowledge cycle time and attribution rate
were largely determined through bibliometric
analysis of clinical guidelines. As part of this study,
and reported separately, we undertook a series ofcase studies that qualitatively explored how research
translates into health benefit [24]. This work
demonstrates the complexity of biomedical and
health innovation, especially when trying to measure
the time it takes for research to develop into health
benefits. Although the bibliometric approach
provides us with an empirical estimate of both the
elapsed time and the rate by which we can attribute
UK research to UK health gain, it inevitably is a
gross simplification of a complex process.
 We have made various assumptions about the
baseline treatment against which we were looking
in research-based developments. For example, in
estimating the net health gain from breast cancer
treatments, we did not include benefits from
standard mastectomy but just estimated the benefits
from subsequent developments.
 There is a risk that we may have double-counted
the NMB for individuals who are treated as a result
of screening. Conceptually, the benefits of screening
include the downstream NMB of treatments that
result from the screening. However, a number of
issues minimise the likelihood of our double
counting. First, we did not include (in the treatment
calculation) all the benefits of treating an individual
disease (for example, breast cancer) but only the
additional benefits of improved (research-based)
treatments, so any additional people who get ‘basic
treatment’ as a result of screening were counted
only as an advantage to screening. Second, the
benefits and the future treatment costs of a woman
entering a screening programme (which is when we
estimated the future QALYs and present value of
associated net costs) occur in a future year, often
many years ahead, so in taking a 20 year period,
there is limited scope for counting both. If we had
perfect data and were looking at all treatment
benefits over a much longer period, we could in
principle look only at the benefits of treatments that
would encapsulate all the QALY benefits of
screening.
In acknowledging these assumptions, we should make
the important point that an underlying principle we
adopted throughout this study and our previous work
on CVD was to err on the side of caution: that is, to
make assumptions that would lead, other things being
equal, to a lower rate of return. However, compared
with our earlier study of CVD, we are less confident that
we have always managed to adhere to the principle of
conservatism. For example, as discussed above, there is
an implicit assumption in ascribing the IRR to the whole
of cancer that everything we have not specifically included
has, in aggregate, no effect on the NMB (the value of the
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the aggregate effect of what we have not considered could
be positive, negative, or zero. Another issue is that in the
CVD study, conservatism often came from adopting the
lower of two (or more) published estimates for specific
parameters, but for cancer interventions, we rarely had a
choice of relevant data estimates, as discussed in more
depth below.
In addition to these specific assumptions, there are a
number of other broader issues that add to the uncertainty
of our estimates and need to be highlighted.
 We have evidence of linkage between research and
health gains but no formal evidence of causality.
Our analysis relied on the reasonable assumption
that these health benefits would not have occurred
without the evidence from medical research, and we
have illustrated the often complex nature of those
linkages in case studies [24]. At one level we have
addressed this issue of causality by our bottom-up
approach, adding together the benefits demonstrated
through clinical trials of new interventions. For
these, causality from worldwide medical research is
all but a truism. However, even for these, we had to
assume that a proportion of the benefit (based on the
UK contribution to publications cited in guidelines)
arose from UK research. It is possible that some or
even all of these interventions might have come into
use in the UK even if there had been no UK cancer
research, but it is improbable that the same level and
timing of benefits would have arisen. Causality
could be argued to be less direct for the benefits of
the reduction in smoking, which made the largest
contribution to the total NMB. It is possible, but
implausible, that changes in smoking behaviour
might have arisen in the absence of any evidence of
the health effects. Certainly, our case studies [24]
show that there was an extended lag between the
initial evidence of harms to smokers and changes
in behaviour, and the UK government probably
needed the cumulative evidence that has emerged
over several decades, and in particular the evidence
of the harms of environmental tobacco smoke, to
make the legislative changes in the face of very
considerable resistance. There are also additional
uncertainties around the magnitudes of NMB from
smoking. Of the total £124 billion total NMB, £80
billion (or 65%) arose from reductions in smoking,
and the numbers for the increased proportion of
the population who were non-smokers or ex-smokers
is based on self-reported survey data. In the sensitivity
analysis (Table 5), if the NMB from smoking reduction
was decreased or increased by (an arbitrary) 25%,
the IRR would reduce to 8.7% or increase to 11.2%respectively. Omitting the benefits from smoking
reduction entirely reduces the IRR to 2.4%. However,
it should be stressed that we estimated only the
mortality effects on lung cancer and excluded effects
on other cancers (and other disease areas) from
smoking, all of which would mean we probably
underestimated the impact of smoking reduction.
However, taking a perspective of NHS costs only,
we have not included costs to other parts of the
economy from the various measures to reduce
smoking [56].
 Variable quality of data on the effectiveness of
screening. The three national screening
programmes are important elements in our
estimates. The clinical and cost-effectiveness evi-
dence for bowel cancer screening is high-quality and
trial-based, but the evidence for cervical screening,
and even more so for breast cancer screening, is less
robust. The
recent review [33] of the clinical evidence has
provided some clarity to the contentious issue of the
net benefits of breast screening, and underpins the
relatively simple economic model that we used as
the basis of our estimate of NMB, but there is
considerable uncertainty around these estimates.
 There is a lack of robust clinical effectiveness and
cost-effectiveness data for some interventions,
especially for longstanding treatments. This was a
general problem with well-established surgical
techniques (for example, total mesorectal excision,
for which no cost-effectiveness evidence could be
found) and similarly for some of the hormonal
therapies (for example, tamoxifen and goserelin).
 There are a large number of areas of cancer that
we did not consider in our analysis. Our analysis
was based on a prioritised list of cancer types
generated from both expert opinion and
epidemiological data. By necessity, this meant we did
not look at a number of areas (and as noted above,
assumed the NMB arising from these areas to be
zero).
 Elapsed time was an important variable in
determining the IRR, but one that is conceptually
difficult to measure [24]. We wanted to measure
the time between research investment and health
gain, but neither of these events occurs at one
defined point. Research investment may occur over
a period, although in many cases, given a typical
pattern of investment starting with pilot trials, and
building to larger-scale studies and finally randomised
controlled trials, the bulk of the research investment
may come late in the overall investment period. The
point at which the bulk of the health gain occurs is
even more difficult to define, and will depend on a
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factors, such as the type of intervention and the way
in which it is implemented. The issue of time lags was
identified in the original 2008 report, which suggested
that further research is needed.
Given these various issues and the nature of the exercise,
which relies on data and estimates from a wide variety of
sources, it is not possible to characterise in any formal way
the overall uncertainty in our estimates. The sensitivity
analysis illustrates the effect on the IRR of alternative
values for some of the key parameters, and shows that
the broad order of magnitude of the IRR is relatively in-
sensitive to fairly substantial degrees of uncertainty on
specific elements of the analysis of what has happened
in the past. Moreover, even without this uncertainty, we
need to interpret our analysis of what has happened in
the past with caution, as follows.
 Past performance is not an indicator of future
performance. The IRR is based on past
performance, and cannot be a guarantee of future
returns, particularly for increased levels of research
spending. This means that research advocates need
to use the estimates provided in this paper very
cautiously if wishing to extrapolate them as
indicators of likely future returns from research
expenditure. Given the near doubling in cancer-
related research funding since the turn of the cen-
tury (Figure 3), there will need to be a similar in-
crease in NMB in the coming decade to maintain
the current returns. It is worth noting that the NMB
of bowel screening is not fully reflected in the IRR
because this screening is of
recent introduction, so there is additional benefit that
will be realised in the future. Likewise, pharmaceutical
interventions are typically priced to maximise the
value of the benefit at time of introduction, so the
NMB is close to zero. During the coming decade,
some of the expensive drugs will come off patent and
may be available more cheaply, thus contributing to an
increase in the NMB; however, other new and expen-
sive ‘on patent’ drugs may well be used in preference.
 We estimated average returns from cancer
research, not the marginal returns. From this
analysis, we are not able to say whether the rate of
return would have been different if research spending
had been higher or lower, and whether at the margin
the returns to research investment are increasing or
diminishing.
 The analysis should not be used to make
comparative assessments about the value of research
into particular interventions/cancers. Our approach
examined a portfolio of interventions/cancer types andwe would caution that the detailed data may not be
sufficiently robust to make comparisons between
interventions within specific cancers.
Future research requirements
Based on the key assumptions, uncertainties and caveats
described above, further research is needed in the follow-
ing areas.
 A deeper understanding of the international flows
of knowledge. In our model, we estimated the
extent to which UK research influences UK
practice, using citations on clinical guidelines, and
this figure was used in estimating the IRR. However,
there is a need for a more nuanced understanding of
these knowledge flows and their impact on
international health gains; for example, UK research
is contributing to health gains beyond the UK. As a
result, our current figure underestimates the global
value of UK R&D. A study that aimed to measure
the health gains, net of healthcare costs, in the rest
of the world as a result of UK medical research
would address this. At a European level, it would
also be interesting to explore how the investments
of different European countries in biomedical and
health research leads to health gains in other
European countries, thereby reinforcing the notion
of European solidarity.
 An improved estimate of spillover effects for UK
biomedical and health research. Public and
charitable biomedical and health research
expenditure not only leads to health gains, but also
makes an important contribution to the national
economy. Much of the evidence base for estimating
a spillover effect of 30% comes from studies
undertaken in the 1960s and 1970s, and/or relates
specifically to agriculture research. More recent
analyses for medical research are largely based on
US data. Furthermore, in this study, we also
assumed that the spillovers are independent of
disease area but we have no empirical evidence to
support whether that assumption is justified or not.
Future research should aim to provide empirical
estimates of the effects of biomedical and health
research for the UK economy, ideally at a
disease-specific level.
 Examine another disease area or time period in
which smoking reduction is likely to have a
minimal impact. As illustrated in Table 5, the IRR
for cancer research is very dependent on the effect
of smoking reduction. It would be valuable to
undertake an investigation in another clinical area in
which smoking is not important to see whether
similar rates of return are found.
The project was conceived by JG and MB, and designed and executed by all
Research UK, the National Institute of Health Research, and the Academy of
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It is challenging to move beyond the identification of the
benefits from specific examples of research funding and
attempt to meet the increasing demands for accountability
by systematically measuring returns to the investment of a
whole body of medical research. In this paper, we have
estimated the economic benefit of public and charitable
funding of cancer-related research, and further validated
the methodological approach that we originally used in
assessing the returns from CVD research. Expressed in
2011/12 prices, total expenditure on cancer-related re-
search from 1970 to 2009 was £15 billion. Over the
period 1991 to 2010, the interventions we prioritised
in our study produced 5.9 million QALYs and a NMB
of £124 billion, allowing for the net NHS costs result-
ing from them, and valuing a QALY at £25,000. The pro-
portion of the benefit attributable to UK research was
17%. The lag between research funding and impact for
cancer treatments was 15 years. Our best estimate of the
health-gain IRR from UK cancer-related research was
10%, very similar to that of 9% for CVD research. The re-
sults suggest that, despite the uncertainties around the
methods and estimates, the historical returns in terms of
the NMB of the health gains derived in the UK from pub-
lic and charitably funded biomedical and health research
are substantial, and could by themselves justify the invest-
ment made.
Endnotes
aWe have used the term ‘interventions’ broadly throughout
this paper to include treatments, screening programmes
and a wide range of policies and information that have led
to changes in smoking.
bNCRI members must have an annual cancer research
spend in the UK in excess of £1 million, and have an ap-
propriate peer-review system for ensuring the scientific
quality of the research that they fund [57].
cUp until 2010, the Wellcome Trust had a policy not to
fund cancer research. It changed its policy in recognition
that the basic research it funded was increasingly having
implications for our understanding of cancer.
dData provided by the Higher Education Funding Council
for England in personal correspondence.
eData provided at our request by NATCANSAT produced
from the national radiotherapy dataset for years 2009 to
2013.
fCWTS maintains a bibliometric database of all scientific
publications (including health and biomedical research)
for the period 1981 to 2013. This dataset is based on the
journals and serials processed for the Internet versions
of the Science Citation Index Expanded and associated
citation indices, the Social Sciences Citation Index, and
the Arts and Humanities Citation Index. This database
is operated for bibliometric purposes in service contractsMedical Sciences. The funders had no influence on the study design, data
collection or analysis, decision to publish, or preparation of the manuscript.
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